E
EYPT
EyePoint
12.93
+0.15+1.17%After Hours: 12.83 -0.10 -0.77%18:32 05/22 EDT
OPEN/PREV CLOSE13.38/13.35
TODAY RANGE12.80-14.02
VOL1.11M
MARKET CAP1.08B
52 WEEK RANGE5.57-19.11
AVG VOL (3M)1.02M
% TURNOVER1.32%
TURNOVER--
P/E (TTM)-3.6878
% RANGE9.18%
EPS(TTM)-3.5007
P/E(FORWARD)0.6689
P/B4.675
BVPS2.762
DIVIDEND--
P/S34.08
BETA--
DIV YIELD0.00%
FREE FLOAT MKT CAP1.02B
SHARES OUTSTANDING83.84M
NEXT EARNINGS08/04-08/10
FREE FLOAT78.90M
LOT SIZE1
EX-DATE12/09/2020
News
Press Releases
Financial Reports
Profile
TipRanks·05/20 03:18
EyePoint Pharma Bets Big on DURAVYU Pivotal Data
Barchart·05/19 06:00
EyePoint Announces Participation at Upcoming Investor Conferences
Reuters·05/18 11:00
EYEPOINT REPORTS INDUCEMENT GRANTS UNDER NASDAQ LISTING RULE 5635(C)(4)
TipRanks·05/14 14:31
EyePoint receives positive DSMC recommendation for Duravyu Phase 3 trials
TipRanks·05/14 11:34
EyePoint Advances DURAVYU Phase 3 Wet AMD Program
Seeking Alpha·05/14 05:58
EyePoint: DURAVYU's Durability Could Drive Significant Upside
TipRanks·05/11 11:43
Mizuho Securities Reaffirms Their Buy Rating on EyePoint Pharmaceuticals (EYPT)
TipRanks·05/08 02:20
EyePoint Pharma Bets on DURAVYU Amid Mounting Losses
Dow Jones·05/07 17:47
EyePoint Pharmaceuticals Price Target Cut to $37.00/Share From $39.00 by RBC Capital
Dow Jones·05/07 17:47
EyePoint Pharmaceuticals Is Maintained at Outperform by RBC Capital
Same Industry
Name/Symbol
Change%
Price
Contact Us
Contact Number :+852 3852 8500Monday 7:00 AM - Saturday 9:00 AM (HKT)
Service Email :service@webull.hkOnline Support: Monday - Friday: 9:00 - 16:00; 22:30 - 5:00 (HKT)
Business Cooperation :marketinghk@webull.hkRisk Disclosure: The content of this page is not an investment advice and does not constitute any offer or solicitation to offer or recommendation of any investment product. It is for general purposes only and does not take into account your individual needs, investment objectives and specific financial circumstances. All investments involve risk and the past performance of securities, or financial products does not guarantee future results or returns. Keep in mind that while diversification may help spread risk it does not assure a profit, or protect against loss, in a down market. There is always the potential of losing money when you invest in securities, or other financial products. Investors should consider their investment objectives and risks carefully before investing. For more details, please refer to risk disclosure.
Webull Securities Limited is licensed with the Securities and Futures Commission of Hong Kong (CE No. BNG700) for carrying out Type 1 License for Dealing in Securities, Type 2 License for Dealing in Futures Contracts and Type 4 License for Advising on Securities.
Webull Securities Limited is licensed with the Securities and Futures Commission of Hong Kong (CE No. BNG700) for carrying out Type 1 License for Dealing in Securities, Type 2 License for Dealing in Futures Contracts and Type 4 License for Advising on Securities.
Language
English
©2026 Webull Securities Limited. All rights reserved.